Impact of lymph node ratio on survival in stage IIIC endometrioid endometrial cancer: a Turkish Gynecologic Oncology Group study by Ayhan, Ali et al.
1/14https://ejgo.org
ABSTRACT
Objective: The purpose of this study was to investigate the prognostic value of lymph node 
ratio (LNR) in women with stage IIIC endometrioid endometrial cancer (EC).
Methods: A multicenter, retrospective department database review was performed to identify 
patients with stage IIIC pure endometrioid EC at 6 gynecologic oncology centers in Turkey. A 
total of 207 women were included. LNR, defined as the percentage of positive lymph nodes 
(LNs) to total nodes recovered, was stratified into 2 groups: LNR1 (≤0.15), and LNR2 (>0.15). 
Kaplan-Meier method was used to generate survival data. Factors predictive of outcome were 
analyzed using Cox proportional hazards models.
Results: One hundred and one (48.8%) were classified as stage IIIC1 and 106 (51.2%) as stage IIIC2. 
The median age at diagnosis was 58 (range, 30–82) and the median duration of follow-up was 40 
months (range, 1–228 months). There were 167 (80.7%) women with LNR ≤0.15, and 40 (19.3%) 
women with LNR >0.15. The 5-year progression-free survival (PFS) rates for LNR ≤0.15 and LNR 
>0.15 were 76.1%, and 58.5%, respectively (p=0.045). An increased LNR was associated with a 
decrease in 5-year overall survival (OS) from 87.0% for LNR ≤0.15 to 62.3% for LNR >0.15 (p=0.005). 
LNR >0.15 was found to be an independent prognostic factor for both PFS (hazard ratio [HR]=2.05; 
95% confidence interval [CI]=1.07–3.93; p=0.03) and OS (HR=3.35; 95% CI=1.57–7.19; p=0.002).
Conclusion: LNR seems to be an independent prognostic factor for decreased PFS and OS in 
stage IIIC pure endometrioid EC.
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Lymph Node Excision; Disease-Free Survival
J Gynecol Oncol. 2018 Jul;29(4):e48
https://doi.org/10.3802/jgo.2018.29.e48
pISSN 2005-0380·eISSN 2005-0399
Original Article
Ali Ayhan ,1 Nazlı Topfedaisi Ozkan ,2 Murat Öz ,2 Günsu Kimyon Comert ,3  
Zeliha Firat Cuylan ,2 Gonca Çoban ,1 Osman Turkmen ,3 Baki Erdem ,4 
Hanifi Şahin ,2 Özgür Akbayır ,4 Murat Dede ,5 Ahmet Taner Turan ,3  
Husnu Celik ,1 Tayfun Güngör ,2 Ali Haberal ,1 Macit Arvas ,6  
Mehmet Mutlu Meydanli  2
1 Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Başkent 
University, Ankara, Turkey
2 Department of Gynecologic Oncology, Zekai Tahir Burak Women's Health Training and Research Hospital, 
Faculty of Medicine, University of Health Sciences, Ankara, Turkey
3 Department of Gynecologic Oncology, Etlik Zübeyde Hanım Women's Health Training and Research 
Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey
4 Department of Gynecologic Oncology, Kanuni Sultan Suleyman Teaching and Research Hospital, Faculty of 
Medicine, University of Health Sciences, Istanbul, Turkey
5 Department of Obstetrics and Gynecology, Gulhane Training and Researh Hospital, Faculty of Medicine, 
University of Health Sciences, Ankara, Turkey
6 Division of Gynecologic Oncology, Department of Gynecologic Oncology, Cerrahpasa Faculty of Medicine, 
Istanbul University, Istanbul, Turkey
Impact of lymph node ratio on survival 
in stage IIIC endometrioid endometrial 
cancer: a Turkish Gynecologic 
Oncology Group study
Received: Dec 1, 2017 
Revised: Jan 22, 2018
Accepted: Feb 19, 2018
Correspondence to
Murat Öz
Department of Gynecologic Oncology,  
Zekai Tahir Burak Women's Health Training 
and Research Hospital, Faculty of Medicine, 
University of Health Sciences, Talatpasa 
Bulvarı, Hamamonu, Altındag/Ankara 06230, 
Turkey.
E-mail: ozmurat@gmail.com
Copyright © 2018. Asian Society of 
Gynecologic Oncology, Korean Society of 
Gynecologic Oncology
This is an Open Access article distributed 
under the terms of the Creative Commons 
Attribution Non-Commercial License (https://
creativecommons.org/licenses/by-nc/4.0/) 
which permits unrestricted non-commercial 
use, distribution, and reproduction in any 
medium, provided the original work is properly 
cited.
ORCID iDs
Ali Ayhan 
https://orcid.org/0000-0001-7155-9096
Nazlı Topfedaisi Ozkan 
https://orcid.org/0000-0001-9399-0637
Murat Öz 
https://orcid.org/0000-0002-0629-5386
Günsu Kimyon Comert 
https://orcid.org/0000-0003-0178-4196
Zeliha Firat Cuylan 
https://orcid.org/0000-0003-3382-8763
Gonca Çoban 
https://orcid.org/0000-0002-3285-5519
Osman Turkmen 
https://orcid.org/0000-0002-1470-7731
Baki Erdem 
https://orcid.org/0000-0002-6407-8718
Hanifi Şahin 
https://orcid.org/0000-0001-8522-9119
Özgür Akbayır 
https://orcid.org/0000-0002-2699-4969
Murat Dede 
https://orcid.org/0000-0002-6361-3256
Ahmet Taner Turan 
https://orcid.org/0000-0001-8120-1143
Husnu Celik 
https://orcid.org/0000-0003-1185-9227
Tayfun Güngör 
https://orcid.org/0000-0002-3261-1186
Ali Haberal 
https://orcid.org/0000-0002-1486-7209
Macit Arvas 
https://orcid.org/0000-0003-2548-1667
Mehmet Mutlu Meydanli 
https://orcid.org/0000-0001-6763-9720
Conflict of Interest
No potential conflict of interest relevant to this 
article was reported.
Author Contributions
Conceptualization: A.A., T.O.N., Ö.M., K.C.G., 
F.C.Z., Ç.G., T.O., E.B., Ş.H., A.Ö., D.M., T.A.T., 
C.H., G.T., H.A., A.M., M.M.M.; Data curation: 
A.A., T.O.N., Ö.M., K.C.G., F.C.Z., Ç.G., T.O., 
E.B., Ş.H., A.Ö., D.M., T.A.T., C.H., G.T., H.A., 
A.M., M.M.M.; Formal analysis: A.A., T.O.N., 
Ö.M., K.C.G., F.C.Z., Ç.G., T.O., E.B., Ş.H., A.Ö., 
D.M., T.A.T., C.H., G.T., H.A., A.M., M.M.M.; 
Investigation: A.A., T.O.N., Ö.M., K.C.G., F.C.Z., 
Ç.G., T.O., E.B., Ş.H., A.Ö., D.M., T.A.T., C.H., 
G.T., H.A., A.M., M.M.M.; Methodology: T.O.N., 
Ö.M., K.C.G., F.C.Z., Ç.G., T.O., E.B., Ş.H., A.Ö., 
D.M., T.A.T., C.H., G.T., H.A., A.M., M.M.M.; 
Project administration: M.M.M.; Resources: 
A.A., A.Ö., D.M., T.A.T., C.H., G.T., H.A., A.M., 
M.M.M.; Software: T.O.N., Ö.M., K.C.G., F.C.Z., 
Ç.G., T.O., E.B., Ş.H., A.Ö., D.M., T.A.T., C.H., 
G.T., H.A., A.M., M.M.M.; Supervision: A.A., 
A.Ö., D.M., T.A.T., C.H., G.T., H.A., A.M., M.M.M.; 
Validation: A.M., M.M.M.; Visualization: A.Ö., 
D.M., T.A.T., C.H., G.T., H.A., A.M., M.M.M.; 
Writing - original draft: A.A., T.O.N., Ö.M., 
K.C.G., F.C.Z., Ç.G., T.O., E.B., Ş.H., A.Ö., D.M., 
T.A.T., C.H., G.T., H.A., A.M., M.M.M.; Writing 
- review & editing: A.A., T.O.N., Ö.M., K.C.G., 
F.C.Z., Ç.G., T.O., E.B., Ş.H., A.Ö., D.M., T.A.T., 
C.H., G.T., H.A., A.M., M.M.M.
INTRODUCTION
Endometrial cancer (EC) patients with positive nodal status show remarkable differences 
in outcome [1] with an estimated 5-year disease-specific survival ranging from 10% to 75% 
[2]. Thus, considerable heterogeneity exists in node-positive patients based on various 
clinicopathologic characteristics [1,3].
The majority of patients who eventually die of disease have positive lymph nodes (LNs) and/
or adverse prognostic factors such as older age, higher tumor grade, or non-endometrioid 
histology [4]. In current clinical practice, patients with positive LNs are offered adjuvant 
platinum based chemotherapy with or without external beam radiation therapy [5]. 
Combination of radiation therapy with chemotherapy (chemoradiotherapy [CRT]), 
(sequential/concurrent), in the adjuvant setting for stage IIIC EC seems to be a safe and 
effective modality [6]. However, CRT has been shown to improve cancer specific survival, 
but not overall survival (OS) [7]. Positive LN status seems to be one of the most important 
prognostic factors in EC. The Gynecologic Oncology Group analysis showed the 5-year 
progression-free survival (PFS) as 90%, 75%, and 38% in EC patients with negative LNs, 
patients with stage IIIC1 and patients with stage IIIC2, respectively [8].
There has been recent interest in using lymph node ratio (LNR) as a prognostic tool in node-
positive EC [2,9,10]. LNR is defined as the number of metastatic LNs divided by the total 
number of LNs removed. Previous studies have found LNR to be associated with a worse PFS 
[2,9,10], and OS [9,10] in EC.
It has been suggested that LNR is most meaningful when comprehensive lymphadenectomy 
is utilized routinely in surgical practice [10]. Additionally, it has been reported that LNR must 
be tied to adjuvant therapy in this patient population [2]. However, previous studies which 
have investigated the prognostic significance of LNR in EC were hampered by the limited 
number of median LNs removed [2,9,10], lack of adjusted adjuvant therapies [9,10], and 
inclusion of non-endometrioid [10] and mixed [2] histologies. The prognostic impact of LNR 
in pure endometrioid EC has not been clearly delineated.
Given the limited number of previous studies on the impact of LNR on survival in 
EC [2,9,10], we conducted this multicenter retrospective analysis aiming at a better 
understanding of the prognostic significance of LNR in endometrioid EC. The purpose of 
this study was to investigate the prognostic value of LNR in patients with stage IIIC [11] pure 
endometrioid EC.
MATERIALS AND METHODS
1. Study design and eligibility
After Institutional Review Board approvals, patients with pure endometrioid EC who underwent 
primary surgical treatment between January 1998 and December 2016 at 6 gynecologic oncology 
centers from Turkey were retrospectively reviewed. All patients gave informed consent for the 
surgical procedure and research use of their medical information at admission.
The study population included women with endometrioid type EC having positive nodal status 
at the end of final pathology report. Women with non-endometrioid type EC, patients with 
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mixed histologies, those with a total number of LNs removed <10 at the end of final pathology 
report, and women with stage IV disease were excluded from the study. We also excluded 
patients with incomplete medical records as well as those with synchronous malignancies.
2. Clinical information
Patient data were extracted from 6 institutions with maintained EC databases. With the 
eligible cases, demographic characteristics were abstracted from medical records. Tumor 
characteristics were abstracted from original pathology reports, and the following data 
were recorded: grade, depth of myometrial invasion (MMI) (<50% or ≥50%), presence of 
lymphovascular space invasion (LVSI) (yes or no), cervical stromal involvement (yes or no), 
adnexal metastasis (yes or no), the status of peritoneal cytology examination (negative 
or positive), and stage of disease. The date of diagnosis, adjuvant treatment modality 
(radiotherapy, CRT, or chemotherapy), recurrence (if applicable), length of follow-up and 
survival were noted. Data were collected from centers with an online standardized form.
Surgical staging consisted of total hysterectomy, bilateral salpingo-oophorectomy, pelvic 
and para-aortic lymphadenectomy, and peritoneal washings. All operations were performed 
by gynecologic oncologists. Data on the extent of surgery included number of total LNs 
harvested, number of pelvic LNs removed, number of para-aortic LNs removed, and number 
of metastatic LNs (total, pelvic, and para-aortic).
All surgical specimens were examined and interpreted by gynecologic pathologists. All 
tumors were staged according to the International Federation of Gynecology and Obstetrics 
(FIGO) staging system [11]. Architectural grading was defined by standard FIGO criteria. 
Notable nuclear atypia inappropriate for the architectural grade raised grade 1 or grade 2 
tumors by one grade. LVSI was defined as the presence of adenocarcinoma of any extent, in 
endothelium lined channels of uterine specimens extracted at the time of surgery [12]. In 
patients treated before 2009, stage was determined retrospectively on the basis of surgical 
and pathologic assessment.
The treatment policies were decided by the attending physician or by the multidisciplinary 
tumor board at each participating institution. Adjuvant therapy was administered to all 
patients. Adjuvant treatment was given based on the following guidelines: 1) extended-field 
irradiation with concurrent/sequential chemotherapy or only chemotherapy for para-aortic 
LN involvement; 2) whole pelvic irradiation for disease limited to the pelvis with negative 
para-aortic LNs; 3) vaginal brachytherapy was offered for all patients undergoing external 
beam therapy. None of the patients in our cohort received adjuvant hormonal therapy. 
The median radiation dose prescribed was 45 Gy for whole pelvis and 54 Gy for extended 
field. The standard primary chemotherapy regimen included paclitaxel 175 mg/m2 plus 
carboplatin dosed at an area under curve of 5 or 6 every 21 days for 6 cycles. The adjuvant 
treatment modalities were not standard within or among the institutions participated in the 
study. CRT was delivered in one of the 2 ways: 3 cycles of chemotherapy upfront, followed 
by radiotherapy, followed by 3 additional cycles of chemotherapy (“sandwich” CRT); or 
radiotherapy with concurrent cisplatin 40 mg/m2 weekly followed by carboplatin area under 
the curve 5 and paclitaxel 175 mg/m2 × 4 cycles. Concurrent chemotherapy with irradiation 
consisted of cisplatin 40 mg/m2 once a week.
Postoperative cancer surveillance included follow-up visits quarterly for the first 2 years, and 
biannually thereafter. A chest radiograph and vaginal smears were obtained once a year. The 
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visits included a gynecologic medical history and a gynecologic examination that was further 
supplemented with biopsies in case of suspicious findings and imaging studies in case of 
suspicion of distant metastases. If an isolated recurrence was diagnosed, treatment with 
curative intent was initiated unless precluded by the patient or disease factors. All women 
included in the study were followed until death or to the end of study period (31st December 
2016). The survival status of the patients was determined as alive or dead at the time of the 
last follow-up. For all study subjects with a recorded death, this was confirmed by performing 
a social security death index search.
3. Definitions
Lymphadenectomy was defined as the performance of pelvic and para-aortic LN dissection 
at the same time. We defined pelvic lymphadenectomy as removal of the lymphatic tissue in 
the external, internal and common iliac and obturator regions. Para-aortic lymphadenectomy 
was defined as removal of the lymphatic tissue over the inferior vena cava and aorta 
beginning at the level of aortic bifurcation up to the left renal vessels.
A systematic lymph node dissection was defined as removal of more than 20 nodes [13]. An 
adequate pelvic lymphadenectomy was defined as the removal of at least 10 pelvic LNs, and 
an adequate para-aortic lymphadenectomy was defined as the removal of at least 5 para-aortic 
LNs [14,15].
After initial diagnosis, recurrence was defined as documentation of metastasis with physical 
examination and/or imaging techniques after a PFS ≥3 months. Progressive disease was 
defined according to the RECIST 1.1 criteria [16]. PFS was defined as the time from surgery 
to the first identification of recurrence or progression, or death from any cause, whichever 
occurred first, or the date of last contact for patients remaining alive without recurrent 
disease. OS was calculated as the time period between initial surgery to the date of death or 
the last contact. Surviving patients were censored at their last known follow-up.
4. Statistical analysis
LNR, defined as the percentage of positive LNs to total nodes recovered, was stratified into 
2 groups: LNR1 (≤0.15), and LNR2 (>0.15). The LNR was arbitrarily set to 0.01 units and 
the log-rank test was performed with OS to determine the appropriate cut-off value [17]. 
Based on the results of these analyses, we used a cut-off value of 0.15, which yielded the most 
significant result and we divided patients into 2 groups according to the LNR, LNR1 (≤0.15), 
and LNR2 (>0.15).
Statistical analyses were performed using the statistical software package SPSS version 23.0 
(IBM Corp., Armonk, NY, USA). The data were expressed as median and range for continuous 
variables. Age ≤60 and >60 years was chosen as age-adjusted variables for both univariate and 
multivariate analyses based on prognostic implications previously reported in the literature 
[18]. Binary variables were reported as counts and percentages.
Survival curves were generated using the Kaplan-Meier method, and the differences between 
survival curves were calculated using the log-rank test. In order to evaluate the prognostic 
factors for PFS and OS, a univariate Cox regression model was used. Any p-value of less than 
0.05 in the univariate analysis was subjected to multivariate analysis. A p-value <0.05 was 
considered to indicate statistical significance.
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RESULTS
During the study period, a total of 236 endometrioid EC with stage III disease were treated at 
6 participating centers. We excluded 10 patients who had less than 10 LNs removed, 1 with 
synchronous breast cancer and 18 women with incomplete medical records. Therefore, the 
present analysis addresses the remaining 207 women with node-positive endometrioid EC.
One hundred and one patients (48.8%) were classified as stage IIIC1 and 106 (51.2%) as stage 
IIIC2. The median age at diagnosis was 58 (range, 30–82) and the median duration of follow-
up was 40 months (range, 1–228 months). Table 1 demonstrates the clinical and pathological 
characteristics of women with stage IIIC pure endometrioid type EC.
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Table 1. Baseline characteristics of the patients
Characteristic Values
Age (yr) 58 (30–82)
<60 114 (55.1)
≥60 93 (44.9)
Grade
1 40 (19.3)
2 97 (46.9)
3 70 (33.8)
Stage
IIIC1 101 (48.8)
IIIC2 106 (51.2)
Lymphovascular space involvement
Negative 38 (18.4)
Positive 169 (81.6)
Cervical stromal involvement
Yes 65 (31.4)
No 142 (68.6)
Adnexal metastasis
Yes 37 (17.9)
No 170 (82.1)
Depth of MMI (%)
50 or less 53 (25.6)
More than 50 154 (74.4)
Peritoneal washings
Negative 175 (84.5)
Positive 32 (14.5)
Adjuvant therapy
Chemotherapy alone 58 (28)
Radiotherapy alone 53 (25.6)
CRT 96 (46.4)
LNR 0.054 (0.006–1.0)
≤0.15 167 (80.7)
>0.15 40 (19.3)
No. of LNs removed (median, [range]) 45 (10–134)
No. of pelvic LNs removed 32 (4–76)
No. of para-aortic LNs removed 14 (1–57)
No. of positive LNs 3 (1–64)
No. of positive pelvic LNs 2 (0–37)
No. of positive para-aortic LNs 1 (0–46)
Status
Alive 177 (85.5)
Dead 30 (14.5)
Values are presented as median (range) or number (%).
CRT, chemoradiotherapy; MMI, myometrial invasion; LN, lymph node; LNR, lymph node ratio.
The median number of total LNs harvested was 45 (range, 10–134). The median number of 
pelvic and para-aortic LNs removed was 32 (range, 4–76), and 14 (range, 1–57), respectively. 
There were 196 women who received systematic LN dissection (94.7%) while 141 women 
(68.1%) had adequate pelvic and adequate para-aortic lymphadenectomy. There were 182 
patients with pelvic LN involvement (87.9%), and 106 patients with para-aortic LN metastases 
(51.2%). Isolated pelvic LN metastasis was detected in 101 women (48.8%). There were 25 
patients with isolated para-aortic LN metastasis (12.1%). Eighty-one patients (39.1%) had 
pelvic and para-aortic LN metastases at the same time. The median number of metastatic 
pelvic and para-aortic LNs was 2 (range, 0–37) and 1 (range, 0–46), respectively. Finally, the 
median number of total metastatic LNs was 3 (range, 1–64).
For the entire cohort, the median LNR was 0.054 (range, 0.006–1.0). There were 167 (80.7%) 
women with LNR1 (≤0.15) and 40 (19.3%) women with LNR2 (>0.15). As depicted in Fig. 1, the 
5-year PFS rates for LNR ≤0.15and LNR >0.15 were 76.1% and 58.5%, respectively (p=0.04). 
Additionally, an increased LNR was associated with a decrease in 5-year OS from 87.0% for 
LNR ≤0.15 to 62.3% for LNR >0.15 (p=0.005) (Fig. 2).
Univariate analysis revealed age ≥60 years (p=0.002), cervical stromal involvement 
(p=0.02) and LNR >0.15 (p=0.02) as significant prognostic factors for decreased 5-year PFS 
(Table 2). At the end of multivariate analysis, age ≥60 years (hazard ratio [HR]=2.96; 95% 
confidence interval [CI]=1.58–5.5; p=0.001), cervical stromal involvement (HR=2.45; 95% 
CI=1.33–4.52; p=0.004) and LNR >0.15 (HR=2.05; 95% CI=1.07–3.93; p=0.03) persisted 
as independent prognostic factors for decreased PFS in women with stage IIIC pure 
endometrioid EC (Table 2).
Univariate analysis revealed age ≥60 years (p=0.002), cervical stromal invasion (p=0.006) 
and LNR >0.15 (p=0.002) as significant factors for decreased OS (Table 3). At the end of 
multivariate analysis, age ≥60 years (HR=3.87; 95% CI=1.74–8.62; p=0.001), cervical stromal 
invasion (HR=3.57; 95% CI=1.7–7.46; p=0.001) and LNR >0.15 (HR=3.35; 95% CI=1.57–7.19; 
p=0.002) remained as independent prognostic factors for decreased OS (Table 3).
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Time (mo)
0.2
0 50 100
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S
0.4
0.6
0.8
1.0
250150 200
p=0.04
LNR2 >0.15
LNR1 ≤0.15
Fig. 1. PFS analyses with regard to LNR (LNR1 ≤0.15 [n=167], LNR2 >0.15 [n=40]). 
LNR, lymph node ratio; PFS, progression-free survival.
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Fig. 2. OS analyses with regard to LNR (LNR1 ≤0.15 [n=167], LNR2 >0.15 [n=40]). 
LNR, lymph node ratio; OS, overall survival.
Table 2. Univariate and multivariate analyses of all patients for PFS
Characteristic No. of events (PFS*) Univariate analyses p HR Multivariate analyses
95% CI p
Age (yr) 0.002 2.96 1.58–5.50 0.001
<60 16/114 (81.8)
≥60 18/93 (61.0)
Grade 0.850
1 7/40 (74.6)
2 22/97 (70.5)
3 14/70 (73.0)
Stage 0.250
IIIC1 19/101 (76.5)
IIIC2 25/106 (69.0)
Lymphovascular space involvement 0.480
Negative 7/38 (73.3)
Positive 36/169 (72.9)
Cervical stromal involvement 0.020 2.45 1.33–4.52 0.004
Yes 19/65 (55.2)
No 25/142 (79.6)
Adnexal metastasis 0.860
Yes 8/37 (72.0)
No 36/170 (73.0)
Depth of MMI (%) 0.070
50 or less 6/53 (83.5)
More than 50 38/154 (68.8)
Peritoneal washings 0.840
Negative 38/175 (72.3)
Positive 6/32 (75.3)
Adjuvant therapy 0.930
Chemotherapy alone 15/58 (66.9)
Radiotherapy alone 13/53 (69.2)
CRT 16/96 (74.6)
LNR 0.020 2.05 1.07–3.93 0.030
≤0.15 31/167 (76.1)
>0.15 13/40 (58.5)
CI, confidence interval; CRT, chemoradiotherapy; HR, hazard ratio; LNR: lymph node ratio; MMI, myometrial invasion; PFS, progression-free survival.
*Five-year PFS (%).
The 5-year PFS rates for stage IIIC1 and IIIC2 disease were 74.5% and 68.0%, respectively 
(p=0.30). Similarly, there was no significant difference in terms of 5-year OS rates between 
stage IIIC1 and IIIC2 disease (86.7% vs. 75.6%, respectively; p=0.24). After stratification by 
substage of the disease, the 5-year PFS rate for women with stage IIIC1 disease and a LNR 
≤0.15 was 74.8% compared to 66.7% for women with stage IIIC1 disease and a LNR >0.15 
(p=0.67). These figures were found to be 74.2% and 55.7%, respectively for stage IIIC2 
disease (p=0.18). The 5-year OS rates did not differ significantly between women with LNR 
≤0.15 and LNR >0.15 in stage IIIC1 disease (88.1% vs. 66.7%, respectively; p=0.21). However, 
the 5-year OS rate for women with stage IIIC2 disease and a LNR ≤0.15 was significantly 
greater than that of women with stage IIIC2 disease and a LNR >0.15 (84.1% vs. 59.8%, 
respectively; p=0.03).
After stratification by adjuvant therapy, there was no significant difference in women receiving 
chemotherapy alone and CRT in terms of PFS and OS with regards to LNRs (Figs. 3 and 4). 
However, LNR >0.15 was significantly associated with a poorer 5-year OS when compared 
to LNR ≤0.15 in patients who received postoperative radiotherapy alone (93.3% vs. 61.4%, 
respectively; p=0.02; Fig. 4).
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Table 3. Univariate and multivariate analyses of all patients for OS
Characteristic No. of events (OS*) Univariate analyses p HR Multivariate analyses
95% CI p
Age (yr) 0.002 3.87 1.74–8.62 0.001
<60 7/114 (90.3)
≥60 15/93 (70.9)
Grade 0.055
1 3/40 (87.7)
2 10/97 (83.9)
3 13/70 (75.1)
Stage 0.580
IIIC1 11/101 (84.5)
IIIC2 12/106 (75.6)
Lymphovascular space involvement 0.160
Negative 1/38 (87.0)
Positive 25/169 (79.1)
Cervical stromal involvement 0.006 3.57 1.7–7.46 0.001
Yes 14/65 (66.1)
No 12/142 (88.7)
Adnexal metastasis 0.16
Yes 5/37 (81.6)
No 21/170 (82)
Depth of MMI (%) 0.070
50 or less 2/53 (95.8)
More than 50 24/154 (76.8)
Peritoneal washings 0.630
Negative 22/175 (82.2)
Positive 4/32 (79.6)
Adjuvant therapy 0.620
Chemotherapy alone 7/58 (78.4)
Radiotherapy alone 6/53 (85.1)
CRT 13/96 (80.0)
LNR 0.002 3.35 1.57–7.19 0.002
≤0.15 15/167 (87.0)
>0.15 11/40 (62.3)
CI, confidence interval; CRT, chemoradiotherapy; HR, hazard ratio; LNR, lymph node ratio; MMI, myometrial invasion; OS, overall survival.
*Five-year OS (%).
There were no patients with progressive disease. However, we have detected 49 recurrences 
during the study period. At the time of reporting, of 207 node-positive women with pure 
endometrioid EC, 177 (85.5%) were alive and 30 (14.5%) were dead.
DISCUSSION
The key findings of the current study indicate that an increased LNR seems to be associated 
with a decrease in 5-year OS from 87% for LNR ≤0.15 to 62.3% for LNR >0.15 in women 
with stage IIIC pure endometrioid EC. Women with LNR >0.15 were 2.05 times more likely 
to have recurrent disease and 3.3 times more likely to die of their tumors when compared to 
women with a LNR ≤0.15. Age ≥60 years, and cervical stromal invasion seem to be the other 
independent prognostic factors for decreased PFS and OS in women with stage IIIC pure 
endometrioid EC.
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Fig. 3. PFS analyses stratified by adjuvant therapy with regard to LNR (LNR1 ≤0.15 [n=167], LNR2 >0.15 [n=40]). (A) Chemotherapy alone, (B) CRT, (C) radiotherapy alone. 
CRT, chemoradiotherapy; LNR, lymph node ratio; PFS, progression-free survival.
The prognostic concept of LNR in EC has emerged during the last decade [2,9,10]. LNR is 
a parameter based on 2 variables; the number of metastatic LNs, and the number of LNs 
removed. If the number of involved LNs is high when the number of removed LNs remains 
relatively limited, then the LNR would appear increased although the quality of LN dissection 
seems questionable. Because of that, we only included women who underwent surgical 
staging with ≥10 nodes removed in the current study. This cut-off (10 as the minimum 
number of LNs removed) has been already used in the subgroup analyses of previous studies 
evaluating the prognostic impact of LNR in EC [2,10]. The number of patients with ≥10 
nodes removed was 81 (65.3%) in the Fleming study [2] whereas the corresponding figure 
was 123 (56.9%) in the study by Polterauer et al. [10]. However, it is important to note that 
the number of nodes recovered may reflect a more extensive dissection, comprehensiveness 
of pathologic evaluation, variations in number of nodes of each patient, and difficulties in 
performing LN dissection due to medical comorbidities [19].
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Fig. 4. OS analyses stratified by adjuvant therapy with regard to LNR (LNR1 ≤0.15 [n=167], LNR2 >0.15 [n=40]). (A) Chemotherapy alone, (B) CRT, (C) radiotherapy alone. 
CRT, chemoradiotherapy; LNR, lymph node ratio; OS, overall survival.
Although sentinel LN navigation surgery is still under validation process [20], sentinel LN 
mapping is currently gaining more respect as an alternative to systematic LN dissection in 
EC. Many gynecologic oncology centers question the necessity of extensive LN dissection in 
patients with stage IIIC disease [21,22]. The Gynecologic Oncology Group recommends that 
a positive pelvic or para-aortic node should indicate no further sampling from that area is 
necessary and that only palpably positive nodes must be sampled for histology [23].
On the contrary, some retrospective studies have shown that more extensive LN dissection 
led to improved survival outcomes pointing out the potential therapeutic benefits of 
comprehensive lymphadenectomy in EC [24,25]. Additionally, recent studies reported a 
survival benefit of resection of LN metastasis and extensive LN dissection for patients with 
advanced disease and LN metastasis [26-28]. Although, the nodal status for EC is categorized 
into stage IIIC1 and IIIC2 based on the metastatic LN location, neither the number of the 
harvested nor the number of the positive LNs have prognostic significance in the current 
FIGO staging system [11].
The prognostic significance of LNR in EC has been addressed in 3 previous studies which 
have revealed that LNR can improve prognostic information [2,9,10]. Chan et al. [9] reported 
from a National Cancer Institute Registry study that an increasing LNR (≤10%, 10%–50%, 
and >50%) in 1,222 node-positive endometrioid ECs (stage IIIC and IV) was associated with 
a decrease in survival from 77.3% to 60.7% to 40.9%, respectively. For patients with stage 
IIIC disease, survival decreased from 78.6% to 66.5% to 65.3%, with regard to the 3 LNR 
groups. However, Chan et al. [9] did not provide details on adjuvant therapy modalities and 
recurrences. They only reported that 63% of their patients received adjuvant radiotherapy. No 
additional information was available on the types of adjuvant therapies received [9].
Polterauer et al. [10] reported a decrease in OS of 79.0%, 60.6%, and 35.8% with increasing 
LNRs of ≤10%, 10%–50%, and >50%, respectively. In multivariate analysis, only LNR was 
associated with both PFS and OS [10]. In the subgroup of patients with stage IIIC EC who 
had at least 10 LNs examined by pathology (n=123), LNR was shown to be a significant 
prognosticator for PFS and OS, whereas the number of removed LNs was not [10]. Polterauer 
et al. [10] included all histologies, of which 30% were non-endometrioid. This may have led 
to a variance in LNR outcomes reported in that study. Additionally, only 13% (n=28) of their 
patients had a LNR >50%; a finding leading to difficulties in order to make any comparisons.
Fleming et al. [2] reported that a LNR >50% showed a significantly worse PFS compared 
to those with LNR ≤10% or 10%–50% in patients with stage IIIC endometrioid EC who 
underwent surgical staging with ≥10 nodes removed. The authors have suggested that LNR 
may define a subgroup of stage IIIC ECs at increased risk of recurrence. It should be noted 
that the median number of pelvic nodes was 9 whereas the median number of para-aortic 
nodes was only 3 in that study. It should be emphasized that women with mixed histologies 
were included if non-endometrioid histology was a minor component (<50%) in the study 
by Fleming et al. [2]. Additionally, the number of patients with a LNR >50% was so small in 
order to draw any definitive conclusions.
While unresectable residual nodal disease in patients with stage IIIC EC is associated 
with rapid progression, the administration of external-beam radiotherapy alone or with 
chemotherapy is associated with an independent survival advantage [29]. Multimodal 
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therapy with both radiation and chemotherapy is now frequently used for women with nodal 
metastases [30]. Accordingly, most of our patients (46.4%) received CRT in the current 
study. We were not able to show the prognostic significance of LNR in women treated with 
CRT or chemotherapy only. However, in the subgroup analysis of women who received 
only radiotherapy as adjuvant treatment, LNR >0.15 was associated with a poorer OS when 
compared to women with a LNR ≤0.15. Since LNR inherently must be tied to adjuvant 
therapy in this patient population [2], we think that stratification of patients with regard to 
different adjuvant treatment modalities is necessary while evaluating the prognostic impact 
of LNR in endometrioid EC. However, the data presented here do not allow us to draw 
definitive conclusions regarding the impact of adjuvant treatment modalities on prognosis in 
this patient population.
We should underline some limitations of the current study. First; the retrospective nature 
of the study cannot exclude any bias. Second, lack of central pathology review seems to be 
an important limitation. Third, adjuvant therapy was administered individually and was not 
standard during the study period. Those shortcomings of our study need to be kept in mind 
while interpreting our findings. Despite above limitations, our study provides additional 
information to the body of knowledge on this topic.
The strengths of the current study lie in its multicenter nature with a large number of patients 
with stage IIIC pure endometrioid EC, performance of uniform staging procedures with 
qualified gynecologic oncologists, and a very high-rate of systematic LN dissection. Our study 
is one of the largest retrospective cohorts associated with the prognostic significance of LNR 
in women with stage IIIC pure endometrioid EC.
In conclusion, the results of our study suggest that LNR is a meaningful prognostic factor in 
stage IIIC pure endometrioid EC. Larger studies including only women who have undergone 
adequate pelvic (at least 10 pelvic nodes removed) and adequate para-aortic (at least 5 para-
aortic nodes removed) lymphadenectomy are needed in order to confirm or deny our findings.
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